Persistent severe inflammation in colonic mucosa is thought to cause the development of colon can... more Persistent severe inflammation in colonic mucosa is thought to cause the development of colon cancer in patients with ulcerative colitis (UC). However, predisposing genetic abnormalities have not been identified in this sequence. Using differential display PCR, we isolated cDNA fragments corresponding to mRNAs that were differentially expressed in colitis-associated cancer tissues and mucosa with mild inflammation in the colon of five UC patients. This molecular screening approach identified 60 cDNA fragments, and we sequenced 34 fragments. One cDNA fragment, which is identical to IFN-inducible gene family 1-8U, was strongly expressed in all five UC-associated cancers. 1-8U was also expressed in sporadic colon cancer tissues and colon cancer cell lines, but not in normal mucosa. This gene was strongly expressed in severely inflamed colonic mucosa of UC without colitis-associated colon cancer, although 1-8U expression was not related to the extent and duration of the disease. However...
Background: Infliximab (IFX) and tacrolimus (Tac) were recently approved for use in refractory ul... more Background: Infliximab (IFX) and tacrolimus (Tac) were recently approved for use in refractory ulcerative colitis (UC) in Japan. There is, however, no consensus on which drug to use first for steroid-refractory UC patients. To clarify the positioning of each drug in the treatment of steroid-refractory
Korean physicians who treat IBD showed high adherence to many of quality measures. However, there... more Korean physicians who treat IBD showed high adherence to many of quality measures. However, there were still performance gaps in IBD care, such as bone loss assessment, influenza and pneumococcal immunization, prophylaxis for venous thrombosis and tobacco cessation intervention, which were similar with Western reports. For quality improvement, it is needed to educate quality measures and to continue to discuss about evidence-based clinical practice guidelines for IBD in Korea.
Serum anticolon antibody and in vitro anti- colon antibody production by peripheral blood and muc... more Serum anticolon antibody and in vitro anti- colon antibody production by peripheral blood and mucosal lymphocytes was investigated in patients with ulcerative colitis. The frequency of serum anticolon antibody was 71% in 41 patients with ulcerative colitis, estimated by enzyme linked immunosorbent assay (ELISA) using isolated rat colon epithelial cells. This finding confirms our previous report on the frequency of serum anticolon antibody detected by flow cytometry analysis. The esti- mated frequencies of IgG anticolon antibody secreting cells were 1.5-12.5/106 cells in the colonic mucosa and 01-05/106 cells in peri- pheral blood, from patients with ulcerative colitis when Epstein-Barr virus (EBV) was used as a B cell polyclonal activator. Poisson analysis of limiting dilution culture showed that about one per 140 IgG cells in the colonic mucosa synthesised anticolon antibody. Two monoclonal IgG antibodies were obtained from EBV transformed anticolon antibody secreting cells by limiting dilution method. One reacted with goblet cells in the intestine, and the other reacted mainly with colonic epithelial cells. These results suggest that heterogeneous anticolon antibodies are present in patients with ulcerative colitis and that colonic mucosa may be the main source of anticolon antibody. Local autoimmune reac- tion might have an important role in causing the inflammation of colonic mucosa in this disease.
Background: We report a multicenter study of oral tacrolimus (FK506) therapy in steroid-refractor... more Background: We report a multicenter study of oral tacrolimus (FK506) therapy in steroid-refractory ulcerative colitis (UC).
Persistent severe inflammation in colonic mucosa is thought to cause the development of colon can... more Persistent severe inflammation in colonic mucosa is thought to cause the development of colon cancer in patients with ulcerative colitis (UC). However, predisposing genetic abnormalities have not been identified in this sequence. Using differential display PCR, we isolated cDNA fragments corresponding to mRNAs that were differentially expressed in colitis-associated cancer tissues and mucosa with mild inflammation in the colon of five UC patients. This molecular screening approach identified 60 cDNA fragments, and we sequenced 34 fragments. One cDNA fragment, which is identical to IFN-inducible gene family 1-8U, was strongly expressed in all five UC-associated cancers. 1-8U was also expressed in sporadic colon cancer tissues and colon cancer cell lines, but not in normal mucosa. This gene was strongly expressed in severely inflamed colonic mucosa of UC without colitis-associated colon cancer, although 1-8U expression was not related to the extent and duration of the disease. However...
Background: Infliximab (IFX) and tacrolimus (Tac) were recently approved for use in refractory ul... more Background: Infliximab (IFX) and tacrolimus (Tac) were recently approved for use in refractory ulcerative colitis (UC) in Japan. There is, however, no consensus on which drug to use first for steroid-refractory UC patients. To clarify the positioning of each drug in the treatment of steroid-refractory
Korean physicians who treat IBD showed high adherence to many of quality measures. However, there... more Korean physicians who treat IBD showed high adherence to many of quality measures. However, there were still performance gaps in IBD care, such as bone loss assessment, influenza and pneumococcal immunization, prophylaxis for venous thrombosis and tobacco cessation intervention, which were similar with Western reports. For quality improvement, it is needed to educate quality measures and to continue to discuss about evidence-based clinical practice guidelines for IBD in Korea.
Serum anticolon antibody and in vitro anti- colon antibody production by peripheral blood and muc... more Serum anticolon antibody and in vitro anti- colon antibody production by peripheral blood and mucosal lymphocytes was investigated in patients with ulcerative colitis. The frequency of serum anticolon antibody was 71% in 41 patients with ulcerative colitis, estimated by enzyme linked immunosorbent assay (ELISA) using isolated rat colon epithelial cells. This finding confirms our previous report on the frequency of serum anticolon antibody detected by flow cytometry analysis. The esti- mated frequencies of IgG anticolon antibody secreting cells were 1.5-12.5/106 cells in the colonic mucosa and 01-05/106 cells in peri- pheral blood, from patients with ulcerative colitis when Epstein-Barr virus (EBV) was used as a B cell polyclonal activator. Poisson analysis of limiting dilution culture showed that about one per 140 IgG cells in the colonic mucosa synthesised anticolon antibody. Two monoclonal IgG antibodies were obtained from EBV transformed anticolon antibody secreting cells by limiting dilution method. One reacted with goblet cells in the intestine, and the other reacted mainly with colonic epithelial cells. These results suggest that heterogeneous anticolon antibodies are present in patients with ulcerative colitis and that colonic mucosa may be the main source of anticolon antibody. Local autoimmune reac- tion might have an important role in causing the inflammation of colonic mucosa in this disease.
Background: We report a multicenter study of oral tacrolimus (FK506) therapy in steroid-refractor... more Background: We report a multicenter study of oral tacrolimus (FK506) therapy in steroid-refractory ulcerative colitis (UC).
Uploads
Papers by H. Ogata